Alphatec Holdings (ATEC) Earnings Date & Reports

Key Takeaways

• Alphatec Holdings (ATEC) reported total revenue of $221 million for the third quarter of 2026, up 13% year over year but below the consensus estimate of roughly $225 million.
• Surgical revenue rose 14% to $202 million, supported by approximately 20% case volume growth and a 25% increase in net new surgeon users.
• GAAP (Generally Accepted Accounting Principles) net loss narrowed to $5 million, or $0.03 per share, from a $28.6 million loss, or $0.19 per share, a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $38 million, or 17.3% of revenue, expanding 400 basis points year over year.
• Management lowered its full-year 2026 total revenue outlook to approximately $862 million and generated $6 million in free cash flow during the quarter.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages covering Alphatec Holdings in detail.
• Explore Trending AI Robots to see AI-driven trading strategies currently drawing attention across the market.

Earnings Context and Why It Matters

Alphatec Holdings is a spine-focused medical device maker that has leaned heavily on procedure-driven growth, competing against much larger rivals in the orthopedic and spine market. Its expansion has been powered by rising case volumes, accelerating surgeon adoption, and a differentiated procedural ecosystem. Because the company is still transitioning toward sustained GAAP profitability, investors track margin expansion, free cash flow, and revenue momentum closely. This quarter's results carry particular weight: any weakness in product attachment or mix can ripple through both top-line growth and the path to profitability. The third-quarter report also updates the full-year outlook, giving investors a clearer read on whether the company's growth trajectory remains intact heading into the year's final quarter.

Reported Results

Alphatec reported total revenue of $221 million for the quarter ended September 30, 2026, a 13% increase from $196.5 million a year earlier but short of the consensus estimate of approximately $225 million. The shortfall was driven primarily by lower biologics attachment, which management acknowledged and said it is addressing. Surgical revenue climbed 14% to $202 million, while surgical hardware revenue increased 17%.

On profitability, GAAP net loss narrowed to $5 million, or $0.03 per share, from a loss of $28.6 million, or $0.19 per share, in the prior-year period. Non-GAAP net income was $15 million. Adjusted EBITDA rose to $38 million, or 17.3% of revenue, up 400 basis points year over year. GAAP gross margin was 71.5%, and the company generated $6 million in free cash flow.

For the full year 2026, management now expects total revenue of approximately $862 million, down from its prior outlook, including roughly $789 million in surgical revenue and $73 million in EOS revenue. Adjusted EBITDA guidance was set at approximately $137 million, with free cash flow expected near $10 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. For investors tracking names like Alphatec Holdings or searching for new setups across the broader market, the AI Screener offers a streamlined way to surface candidates worth a closer look.

Market Reaction and Investor Sentiment

Alphatec's third-quarter report delivered a mixed message to investors. The company's underlying surgical demand remained robust, with double-digit growth in hardware revenue, case volumes, and surgeon adoption reinforcing the core growth narrative. At the same time, the revenue miss tied to weaker biologics attachment and the downward revision to full-year guidance raised questions about near-term execution and product mix. Sentiment heading into the report had been cautious, with shares trading well below their 52-week high, and analysts holding a broadly positive but watchful view of the growth story. The post-earnings reaction likely reflects investors weighing durable procedural momentum against the biologics shortfall and the lowered outlook.

Forward Outlook and Key Factors to Monitor

Following the report, investors will focus on whether management can execute on its stated priority of improving biologics performance. Lower biologics attachment was the primary driver of the revenue miss, and any progress on that front could help close the gap between strong surgical demand and total revenue translation.

Margin and cash flow trends also remain central. Adjusted EBITDA margin expanded by 400 basis points year over year to 17.3%, and the company generated positive free cash flow. Sustaining that leverage while investing in new products and surgeon adoption will be a key test in the coming quarters.

Additionally, watch the adoption of the company's newer technologies and platforms, which management has positioned as differentiators in the competitive spine market. Case volume growth and net new surgeon additions offer an important read on demand durability. Finally, investors should monitor the company's full-year guidance and any commentary on the fourth quarter, as well as broader industry conditions such as procedure volumes, hospital capital spending, and reimbursement dynamics.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations